Overview of original papers published in 2012

The following original papers were published by members of the German Breast Group in 2012:

Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, Fehm T, Van Calsteren K, Linn SC, Schlehe B, Gziri MM, Westenend PJ, Müller V, Heyns L, Rack B, Van Calster B, Harbeck N, Lenhard M, Halaska MJ, Kaufmann M, Nekljudova V, Amant F: Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 13(9):887-96, 2012

Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A; on behalf of the AGO and GINECO study group: The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 23(10):2605-2612, 2012

Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Fasching PA, Mau C, Schem C, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Müller V: Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab - a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer. 107(6):956-60, 2012

Ditsch N, Vodermaier A, Hinke A, Burghardt S, Lenhard M, Löhrs B, Toth B, VON Koch F, Kahlert S, Bauerfeind I, Konecny GE, Loibl S, von Minckwitz G, Untch M: Dose-dense Intensified Sequential Versus Conventionally-dosed Anthracycline and Taxane-containing Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer. Anticancer Res. 32(8):3539-45, 2012

Massey Skatulla L, Loibl S, Schauf B, Müller T: Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature. Arch Gynecol Obstet. 286(1):89-92, 2012

Loibl S, Han SN, Amant F: Being Pregnant and Diagnosed with Breast Cancer. Breast Care (Basel 7(3):204-209, 2012

Denkert C, Bucher E, Hilvo M, Salek R, Orešč M, Griffin J, Brockmöller S, Klauschen F, Loibl S, Barupal DK, Budczies J, Iljin K, Nekljudova V, Fiehn O: Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med. 4(4):37, 2012

von Minckwitz G, Untch M, Blohmer J-U, Costa S-D, Eidtmann H, Fasching P.A, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny G, Denkert C, Nekljudova V, Mehta K, Loibl S for the GBG and AGO-B study groups: Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 30(15):1796-804, 2012

Azim HA Jr, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, Gresko E, Arfi M, Piccart-Gebhart M: Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat. 133(1):387-91, 2012

Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Reed M, Ciatto S, Voogd AC, Brain E, Cutuli B, Terret C, Gosney M, Aapro M, Audisio R: Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 13(4):e148-60, 2012

von Minckwitz G, Nekljudova V, Loibl S: What can be learned from trials running short of patients or events? J Clin Oncol. 30(9):901-3, 2012

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 366(4):299-309, 2012

Chan A, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, Vandenberg T: Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol. 81(2):136-50, 2012

Brockmöller SF, Bucher E, Müller BM, Budczies J, Hilvo M, Griffin JL, Orešič M, Kallioniemi O, Iljin K, Loibl S, Darb-Esfahani S, Sinn BV, Klauschen F, Prinzler J, Bangemann N, Ismaeel F, Fiehn O, Dietel M, Denkert C: Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer - link to patient survival, hormone receptor status and metabolic profiling. J Proteome Res. 11(2):850-60, 2012

Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G; for the German Breast Group (GBG); the Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group: Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 13(2):135-144, 2012

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 366(4):299-309, 2012